Quest Diagnostics Inc (DGX) : Aston Asset Management reduced its stake in Quest Diagnostics Inc by 9.36% during the most recent quarter end. The investment management company now holds a total of 45,158 shares of Quest Diagnostics Inc which is valued at $3,874,105 after selling 4,661 shares in Quest Diagnostics Inc , the firm said in a disclosure report filed with the SEC on Aug 11, 2016.Quest Diagnostics Inc makes up approximately 2.25% of Aston Asset Management’s portfolio.
Other Hedge Funds, Including , Comerica Bank reduced its stake in DGX by selling 576 shares or 1.58% in the most recent quarter. The Hedge Fund company now holds 35,832 shares of DGX which is valued at $3,074,027. Quest Diagnostics Inc makes up approx 0.03% of Comerica Bank’s portfolio.Cable Hill Partners boosted its stake in DGX in the latest quarter, The investment management firm added 22 additional shares and now holds a total of 72 shares of Quest Diagnostics Inc which is valued at $6,169.Quantitative Investment Management reduced its stake in DGX by selling 13,900 shares or 46.18% in the most recent quarter. The Hedge Fund company now holds 16,200 shares of DGX which is valued at $1,387,530. Quest Diagnostics Inc makes up approx 0.06% of Quantitative Investment Management’s portfolio. Clean Yield Group added DGX to its portfolio by purchasing 6,600 company shares during the most recent quarter which is valued at $556,446. Quest Diagnostics Inc makes up approx 0.24% of Clean Yield Group’s portfolio.Foundry Partners boosted its stake in DGX in the latest quarter, The investment management firm added 7,714 additional shares and now holds a total of 137,344 shares of Quest Diagnostics Inc which is valued at $11,413,286. Quest Diagnostics Inc makes up approx 1.07% of Foundry Partners’s portfolio.
Quest Diagnostics Inc closed down -0.62 points or -0.73% at $84.48 with 13,63,606 shares getting traded on Tuesday. Post opening the session at $85.3, the shares hit an intraday low of $84.38 and an intraday high of $85.45 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
On the company’s financial health, Quest Diagnostics Inc reported $1.34 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 21, 2016. Analyst had a consensus of $1.32. The company had revenue of $1906.00 million for the quarter, compared to analysts expectations of $1905.57 million. The company’s revenue was down -1.0 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.25 EPS.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business consists of two parts develops and delivers diagnostic testing information and services to patients physicians health plans hospitals accountable care organizations (ACOs) integrated delivery networks (IDNs) other commercial laboratories patients and other customers. Diagnostics Information Services business also provides diagnostic information services which includes providing clinical testing services such as routine testing gene-based and esoteric testing anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses including central laboratory testing for pharmaceutical and medical device clinical trials risk assessment services diagnostic products and healthcare information technology.